The role of lanreotide in the treatment of choroidal neovascularization secondary to age-related macular degeneration: A pilot clinical trial

Retina

Volumn 23, Issue 6, 2003, Pages 800-807

  Papadaki, Thekla ^a   Tsilimbaris, Miltiadis ^a,b   Thermos, Kyriaki ^a   Karavellas, Marieta ^a   Samonakis, Dimitrios ^a   Papapdakis, Antonis ^b   Linardakis, Manolis ^c   Kouromalis, Elias ^a   Pallikaris, Ioannis ^a  

^a Medical Imaging Laboratory   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Clinical study; Intramuscular injection; Lanreotide; Placebo; Somatostatin

Indexed keywords

ANGIOPEPTIN; PLACEBO; SOMATOSTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DIARRHEA; DOCUMENTATION; DRUG WITHDRAWAL; EYE; FEMALE; FLUORESCENCE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; STATISTICAL ANALYSIS; SUBRETINAL NEOVASCULARIZATION; SURFACE PROPERTY; VISUAL ACUITY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOROIDAL NEOVASCULARIZATION; DRUG EVALUATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MACULAR DEGENERATION; MALE; PEPTIDES, CYCLIC; PILOT PROJECTS; PROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 0346731197     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200312000-00010     Document Type: Article

References (30)

1. Fine S, Berger J, Maguire M, et al. Age-related macular degeneration. N Engl J Med 2000;342:483-492.
2. Green R, Enger C. Age-related macular degeneration histopathologic studies. Ophthalmology 1993;100:1519-1535.
3. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-1114.
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol 1997;117:1329-1345.
5. Campochiaro P, Soloway P, Ryan S, Miller J. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis 1999;5:34.
6. Pharmacological Therapy for Macular Degeneration Study Group. Interferon A2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1997;115:865-872.
7. Guyer DR, Adamis AP, Gragoudas ES, et al. Systemic antiangiogenic therapy for choroidal neovascularization: what is the role of interferon alpha? Arch Ophthalmol 1992;110:1383-1384.
8. Brown N. Octreotide. A long-acting somatostatin analogue. Am J Med Sci 1990;300:267-273.
9. Smith L, Kopchik J, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997;276:1706-1709.
10. Danesi R, Del Tacca M. The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism 1996;8(suppl):49-50.
11. Lang GE, Kave C, Spraul G, Lang GK. Effect of octreotide on RPE cell proliferation in vitro (abstract). Invest Ophthalmol Vis Sci 2000;41:S605.
12. Lambooij A, Kuijpers R, van-Lichtenauer-Kaligis FG, et al. Somatostatin receptor 2A expression in choroidal neovascularization secondary to AMD. Invest Ophthalmol Vis Sci 2000;41:2329-2335.
13. Klisovic D, O'Dorsio M, Katz S, et al. Somatostatin receptor (SSTR) gene expression in human ocular tissues. Invest Ophthalmol Vis Sci 2001;42:2193-2201.
14. Rapantzikos K, Zervakis M, Balas K. Detection and segmentation of drusen deposits on human retina: potential in the diagnosis of age-related macular degeneration. Med Image Anal 2003;7:95-108.
15. van Hagen P, Baarsma G, Mooy C, et al. Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 2000;143:43-51.
16. Kuijpers R, Baarsma S, van Hagen P. Treatment of cystoid macular edema with octreotide (letter). N Engl J Med 1998;338:624-626.
17. Eagle R. Mechanisms of maculopathy. Ophthalmology 1984;91:613-625.
18. Liapakis G, Politou E, Thermos K. Solubilization of somatostatin receptors from rabbit retina. Biochem Pharmacol 1993;45:1821-1828.
19. Vasilaki A, Gardette R, Epelbaum J, Thermos K. NADPH-diaphorase colocalizes with somatostatin receptor subtypes sst2A and sst2B in the rat and rabbit retina. Invest Ophthalmol Vis Sci 2001;42:1600-1609.
20. Johnson, J, Wu V, Wong H, Walsh JH, Brecha NC, Somatostatin receptor subtype 2A expression in the rat retina. Neuroscience 1999;94:675-683.
21. Helboe L, Moller M. Immunohistochemical localization of somatostatin receptor subtypes sst1 and sst2 in the rat retina. Invest Ophthalmol Vis Sci 1999;40:2376-2382.
22. Johnson J, Rickman DW, Brecha NC. Somatostatin and somatostatin subtype 2A expression in the mammalian retina. Microsc Res Tech 2000;50:103-111.
23. Grant M, Caballero S, Millard W. Inhibition of IFG-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue octreotide: a potential treatment for ocular neovascularization. Regul Pept 1993;43:267-278.
24. Mallet B, Vialletes B, Haroche S, et al. Stabilization of severe proliferative diabetic retinopathy by long treatment with SMS 201-995. Diabetes Metab 1992;18:438-444.
25. Mc Combe M, Lightman S, Eckland D, et al. Effect of a long-term somatostatin analogue (BIM 23014) on proliferative diabetic retinopathy: a pilot study. Eye 1991;5:569-575.
26. Grant M, Mames R, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000;23:504-509.
27. Kuijpers R, Baarsma S, van Hagen P. Treatment of cystoid macular edema with octreotide (letter). N Engl J Med 1998;338:624-626.
28. Krassas GE, Kaltsas T, Dumas A, et al. Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 1997;136:416-422.
29. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000;41:1186-1191.
30. Boehm BO, Lang GK, Jehle PM, et al. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001;33:300-306.